tipifarnib has been researched along with Glial Cell Tumors in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyett, JM; Geyer, R; Haas-Kogan, D; Kieran, MW; Kun, L; Ng, S; Pollack, IF; Poussaint, TY; Prabhu, SP; Vajapeyam, S | 1 |
| Boyett, JM; Cha, S; Geyer, R; Haas-Kogan, D; Kocak, M; Kun, LE; Packer, RI; Patay, Z; Pollack, IF; Poussaint, TY; Robertson, RL; Vajapeyam, S; Vezina, G; Zimmerman, R | 1 |
| Bonnet, J; Cohen-Jonathan, E; Delmas, C; End, D; Favre, G; Heliez, C; Toulas, C | 1 |
| Cohen-Jonathan, E; Delmas, C; End, D; Favre, G; Rochaix, P; Toulas, C | 1 |
| Abrey, L; Chang, S; Cloughesy, TF; DeAngelis, L; Fink, K; Groves, M; Junck, L; Kuhn, J; Lamborn, K; Lieberman, FS; Mehta, M; Paquette, S; Prados, M; Robins, HI; Schiff, D; Sebti, SM; Wen, P; Wright, J; Yung, A | 1 |
| Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; DeAngelis, LM; Fink, KL; Gilbert, MR; Groves, MD; Junck, L; Kuhn, J; Lamborn, KR; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Schiff, D; Wen, PY; Wright, J; Yung, WK | 1 |
| Cohen, K; Fouladi, M; Helton, KJ; Holmes, E; Laningham, F; Nicholson, HS; Pollack, IF; Speights, RA; Wright, J; Zhou, T | 1 |
| Banerjee, A; Blaney, SM; Boyett, JM; Broniscer, A; Fouladi, M; Geyer, JR; Haas-Kogan, DA; Kocak, M; Kun, LE; McKnight, T; Poussaint, TY; Prados, MD | 1 |
4 trial(s) available for tipifarnib and Glial Cell Tumors
| Article | Year |
|---|---|
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinolones; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Induction; Epilepsy; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Quinolones; Treatment Outcome | 2006 |
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Male; Medulloblastoma; Neuroectodermal Tumors; Quinolones; Treatment Outcome | 2007 |
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Quinolones; Radiotherapy | 2008 |
4 other study(ies) available for tipifarnib and Glial Cell Tumors
| Article | Year |
|---|---|
DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Anisotropy; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diffusion Tensor Imaging; Gefitinib; Glioma; Humans; Image Interpretation, Computer-Assisted; Male; Nerve Fibers, Myelinated; Quinazolines; Quinolones; Radiotherapy | 2011 |
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Diffusion; Female; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Quinazolines; Quinolones; Radiotherapy Dosage; Research Design; Survival Rate; Treatment Outcome | 2011 |
Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.
Topics: Alkyl and Aryl Transferases; Cell Death; Cell Survival; Enzyme Inhibitors; Farnesyltranstransferase; Gene Expression; Genes, ras; Glioma; Humans; Mutation; Quinolones; Radiation-Sensitizing Agents; ras Proteins; rhoB GTP-Binding Protein; Transfection; Tumor Cells, Cultured | 2002 |
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Hypoxia; Enzyme Inhibitors; Farnesyltranstransferase; Glioblastoma; Glioma; Humans; Immunoenzyme Techniques; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinolones; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |